Home / Health / Insulin Inhaler Approved for Diabetic Kids
Insulin Inhaler Approved for Diabetic Kids
29 May
Summary
- FDA approves MannKind's inhaled insulin for children with diabetes.
- This offers a needle-free treatment option for patients under 18.
- Eligible young patients can access Afrezza for $35 or less monthly.
In a significant development for pediatric diabetes care, the U.S. Food and Drug Administration (FDA) has granted expanded approval for MannKind's Afrezza, an inhaled rapid-acting insulin. This approval specifically targets children diagnosed with diabetes, offering a vital needle-free treatment alternative for individuals under the age of 18. The decision broadens treatment options for younger patients who rely on multiple daily insulin administrations to effectively manage their blood sugar levels. MannKind announced that eligible patients can obtain Afrezza for a cost of $35 or less per month. This advancement marks a key milestone in making diabetes management more accessible and less invasive for pediatric populations. Shares of MannKind experienced a notable increase of 5% in afternoon trading following the news.
